4-氯烟酰氯化物 | 100791-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氯烟酰氯化物
• 英文名称: 4-chloronicotinoyl chloride
• 英文别名: 4-chloropyridine-3-carbonyl chloride
• CAS: 100791-00-2
• 化学式: C₆H₃Cl₂NO
• mdl: MFCD09864939
• 分子量: 176.002
• InChiKey: CSQKICWPCREIJP-UHFFFAOYSA-N

物化性质

• 沸点：
  243.9±20.0 °C(Predicted)
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-氯烟酰氯化物 在 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 4-(quinolin-8-yloxy)nicotinate
  参考文献：
  名称：

  4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists

  摘要：

  A series of 4-benzofuranyloxynicotinamide derivatives were identified to be novel, potent, and orally available TGR5 agonists. Among them, compound 9r had the highest potency in vitro (hTGR5 EC50 = 0.28 nM, mTGR5 EC50 = 0.92 nM). Further in vivo studies disclosed that 9r could effectively lower the blood glucose, but meantime caused an increase in the gallbladder volume of mice. Subsequent research toward eliminating the gallbladder toxicity resulted in compound 19 with low permeability. Although the EC50 of mTGR5 of 19 was larger one order than that of 9r, it still had good glucose-lowing activity. Nevertheless, 19 also caused the adverse effects to the gallbladder. The drug levels detection disclosed that the concentration of 19 was only lower than that of 9r in plasma but was higher in bile and gallbladder tissue. This result indicated that low exposure in plasma could not guarantee low exposure in bile and gallbladder tissue, and thus resulting in the gallbladder toxicity of 19. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.031
• 作为产物：
  描述：

  4-氯烟酸 在 氯化亚砜 作用下， 反应 24.0h， 生成 4-氯烟酰氯化物
  参考文献：
  名称：

  使用 (EtO)3P 作为还原剂和空气中的 O2 作为末端氧化剂，苯并异噻唑酮有机/铜共催化氧化还原羧酸酰胺和肽的脱水构建

  摘要：

  使用催化量的具有氧化还原活性的苯并异噻唑酮和铜络合物，羧酸和胺/氨基酸反应物可以在 50°C 下在 5-36 小时内在中性 pH 值下转化为酰胺和肽。这些催化“氧化-还原缩合”反应在干燥空气中进行，使用O 2 作为末端氧化剂和稍微过量的亚磷酸三乙酯作为还原剂。磷酸三乙酯是容易去除的副产物。这些易于运行的催化反应为 CN 键的酰化构建提供了实用且经济的方法。

  DOI：

  10.1021/jacs.6b03168

文献信息

• [EN] ARYL ETHER-BASE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE ARYLÉTHER-BASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015038112A1

  公开（公告）日：2015-03-19

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR
  申请人：Daito Chemix Corporation

  公开号：US20150259321A1

  公开（公告）日：2015-09-17

  According to an embodiment of the present invention, there is provided a novel fluorene-based compound and a photopolymerization initiator using the fluorene-based compound. The fluorene-based compound according to an embodiment of the present invention is represented by the general formula (1). A photopolymerization initiator having additionally high sensitivity can be provided by using the fluorene-based compound. In addition, a photopolymerization initiator that can impart additionally excellent characteristics can be provided by appropriately selecting, for example, a substituent.

  根据本发明实施例，提供了一种新的基于芴的化合物和使用该基于芴的化合物的光聚合引发剂。根据本发明实施例，基于芴的化合物由通式（1）表示。通过使用基于芴的化合物，可以提供具有更高灵敏度的光聚合引发剂。此外，通过适当选择例如取代基，可以提供具有额外优异特性的光聚合引发剂。
• [EN] HINDERED DISULFIDE DRUG CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENTEUX À PONT DISULFURE ENCOMBRÉ
  申请人：GENENTECH INC

  公开号：WO2017064675A1

  公开（公告）日：2017-04-20

  The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

  该发明一般涉及二硫键药物偶联物，其中含有至少一个被至少一个碳氢化合物或取代碳氢化合物所取代的含硫碳原子的连接剂通过二硫键与靶向载体的半胱氨酸硫原子偶联，并且连接剂进一步与药物部分偶联。该发明进一步涉及适合通过二硫键与靶向载体偶联的活化连接剂-药物偶联物。该发明还进一步涉及制备受阻二硫键药物偶联物的方法。
• SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS
  申请人：GRÜNENTHAL GMBH

  公开号：US20140148468A1

  公开（公告）日：2014-05-29

  The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

  这项发明涉及特定的羧酰胺，涉及它们的制备过程，包括这些化合物的药物以及这些化合物在药物制备中的应用。
• [EN] SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS<br/>[FR] CARBOXAMIDES SPÉCIFIQUES UTILISÉS EN TANT QUE MODULATEURS DES CANAUX KCNQ2/3
  申请人：GRUENENTHAL CHEMIE

  公开号：WO2014082737A1

  公开（公告）日：2014-06-05

  The invention relates to specific carboxamides of formula (I) as KCNQ2/3 modulators, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

  该发明涉及公式（I）的特定羧酰胺作为KCNQ2/3调节剂，涉及其制备方法，包括这些化合物的药物以及这些化合物在药物制备中的应用。